In the assessment of 12-month price targets, analysts unveil insights for 10x Genomics, presenting an average target of ...
10x Genomics missed estimated earnings by -30.0%, reporting an EPS of $-0.13 versus an estimate of $-0.1. Revenue was up $1.01 million from the same period last year. Last quarter the company missed ...
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on 10x Genomics (NASDAQ:TXG) in the last three months. The following table summarizes their recent ...
Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $166 million. The company expects the full year’s ...
Zacks Investment Research on MSN
10x Genomics (TXG) reports Q4 loss, beats revenue estimates
10x Genomics (TXG) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.4 per share a year ago. These figures are ...
8 analysts have shared their evaluations of 10x Genomics (NASDAQ:TXG) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...
Hosted on MSN
Brown Capital Management Small Company Fund Sold 10x Genomics (TXG) Due to Fundamental Concerns
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded ...
PLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...
PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to ...
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling BRISBANE, Calif.-- ...
Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results